PrivatePulse·Companies·Benchling vs Ro

Benchling vs Ro: employee equity compared

Secondary market prices, valuation trajectory, equity structure, and liquidity outlook for employees choosing between Benchling and Ro.

Secondary signals manually reviewed · Sources: Hiive, Forge · Not tradable prices
One or both companies have weak model support. Treat this comparison as directional only.

Benchling

Healthcare · United States · Founded 2012

Life science R&D platform combining electronic lab notebook, molecular biology tools, and LIMS (lab information management) for biopharma, biotech, and agricultural science.

Last primary round$6.1B · Series E (2021-01)
Secondary marketNo recent verified signal
Annual revenue$0.1B ARR · +30% YoY (solid)
Headcount~700
Equity typeISO/NSO
Strike price range$18–$30 (depends on cohort)
Illiquidity discount~25%
Last round leadCoatue Management
Liquidity outlook

No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.

Key equity angle

Healthcare tech with long sales cycles; ISO/NSO options; regulatory milestones drive value

Data quality
Secondary: No verified signal — last primary only
Revenue: Disclosed

Ro

Healthcare · United States · Founded 2017

Telehealth platform offering primary care, men's health, women's health, and weight management through 50-state provider network and fully integrated pharmacy.

Last primary round$5B · Series D (2021-03)
Secondary marketNo recent verified signal
Annual revenue$0.6B ARR · +25% YoY (solid)
Headcount~1,200
Equity typeISO/NSO
Strike price range$16–$26 (depends on cohort)
Illiquidity discount~25%
Last round leadGeneral Catalyst
Liquidity outlook

No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.

Key equity angle

Healthcare tech with long sales cycles; ISO/NSO options; regulatory milestones drive value

Data quality
Secondary: No verified signal — last primary only
Revenue: Disclosed

Key differences for employees

Equity structure

Benchling grants ISO/NSO with strike prices ranging from $18–$30 depending on your grant year. Ro grants ISO/NSO with strike prices from $16–$26.

Secondary market signal

Benchling has no recent verified secondary signal — only the primary round ($6.1B) is shown. Ro has no recent verified secondary signal. A higher secondary premium typically signals stronger investor demand and potentially better near-term liquidity for employees looking to sell.

Revenue and growth

Benchling runs at $0.1B ARR, growing +30% YoY (solid). Ro runs at $0.6B ARR, growing +25% YoY (solid). Revenue growth rate matters for equity because it drives the peer-multiple valuation — the method most correlated with exit multiples.

Liquidity timeline

Benchling: No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.

Ro: No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.

Calculate your specific grant

Enter your actual shares, equity type, and strike price. PrivatePulse calculates your personal equity value using peer-multiple, secondary-market, time-decay, and sector-momentum methods.

Frequently asked questions

Is Benchling or Ro a better company to work at for equity?
There's no universal answer — it depends on your risk profile, time horizon, and specific grant terms. Benchling at $6.1B and Ro at $5B offer very different risk/reward profiles. Use the calculator above to model your exact grant at each company.
How do I know if my Benchling or Ro equity is fairly priced?
Compare your grant's implied per-share value against the secondary market price. If investors are paying a premium on Hiive or Forge over the last primary round, that's a signal of strong demand. PrivatePulse shows you the gap between your 409A and what the secondary market says.
Can I sell my Benchling or Ro shares on the secondary market?
Secondary market transactions (Hiive, Forge, Caplight) require accredited investor status and your company's consent — most private companies have right-of-first-refusal (ROFR) provisions. Tender offers, when available, are typically the most accessible path to partial liquidity for employees.

More equity comparisons